Research programme: fms-like tyrosine kinase 3 inhibitors - Antisoma/Johns Hopkins

Drug Profile

Research programme: fms-like tyrosine kinase 3 inhibitors - Antisoma/Johns Hopkins

Alternative Names: DCAMs - Antisoma

Latest Information Update: 15 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer Antisoma
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 20 May 2010 Antisoma is looking for a licensing partnership for the programme
  • 11 Jun 2008 Xanthus Pharmaceuticals has been acquired and merged into Antisoma
  • 16 Apr 2007 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top